Compounds and compositions as modulators of gpr119 activity

A compound of Formula I:

• in which:
• Q is a divalent or trivalent radical selected from C6-10aryl, C1-10heteroaryl, C3-8cycloalkyl and C3-8heterocycloalkyl;
• wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of Q is optionally substituted with up to 3 radicals independently selected from halo, C1-6alkyl, halo-substituted-C1-6alkyl, C1-6alkoxy, halo-substituted-C1-6alkoxy, —C(O)R20 and —C(O)OR20;
• wherein R20 is selected from hydrogen and C1-6alkyl;
• and optionally connecting a carbon adjacent to W2 through a CR31, O, S or NR31 with a carbon of Q to form a 5-membered ring fused to rings A and Q;
• wherein R31 is selected from hydrogen and C1-6alkyl;
• W1 and W2 are independently selected from CR21 and N;
• wherein R21 is selected from hydrogen, cyano, C1-6alkyl and —C(O)OR25;
• wherein R25 is selected from hydrogen and C1-6alkyl;
• ring A can have up to 2 ring carbons substituted with a group selected from —C(O)—, —C(S)— and —C(═NOR30)— and can be partially unsaturated with up to 2 double bonds;
• wherein R30 is selected from hydrogen and C1-6alkyl;
• L is selected from C1-6alkylene, C2-6alkenylene, —(CH2)nO—, —OC(O)(CH2)n—, —C(O)O(CH2)n—, —NR26(CH2)n— and —O(CH2)n—;
• wherein R26 is selected from hydrogen and C1-6alkyl;
• and n is selected from 0, 1, 2, 3, 4 and 5;
• wherein any alkyl of L can be optionally substituted with 1 to 3 radicals independently selected from halo, C1-6alkyl, halo-substituted-C1-6alkyl, C1-6alkoxy, halo-substituted-C1-6alkoxy, —C(O)R22 and —C(O)OR22;
• wherein R22 is selected from hydrogen and C1-6alkyl;
• m is selected from 0, 1, 2, 3 and 4;
• q is selected from 0, 1, 2, 3 and 4;
• t1 t2, t3 and t4 are each independently selected from 0, 1 and 2;
• R1 is selected from —X1S(O)0-2X2R6a, —X1S(O)0-2X2OR6a, —X1S(O)0-2X2C(O)R6a, —X1S(O)0-2X2C(O)OR6a, —X1S(O)0-2X2OC(O)R6a and —X1S(O)0-2NR6aR6b;
• wherein X1 is selected from a bond, O, NR7aR7b and C1-4alkylene;
• X2 is selected from a bond and C1-4alkylene;
• R6a is selected from hydrogen, halo, C1-6alkyl, C2-6alkenyl, C6-10aryl, C1-10heteroaryl, C3-8heterocycloalkyl and C3-8cycloalkyl;
• wherein said aryl, heteroaryl, cycloalkyl and heterocycloalkyl of R6a is optionally substituted with 1 to 3 radicals independently selected from hydroxy, halo, C1-6alkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, cyano-substituted-C1-6alkyl, C1-6alkoxy, halo-substituted-C1-6alkoxy and C6-10aryl-C1-4alkoxy;
• R6b is selected from hydrogen and C1-6alkyl;
• and R7a and R7b are independently selected from hydrogen and C1-6alkyl;
• R2 and R3 are independently selected from hydrogen, halo, hydroxy, C1-6alkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, C1-6alkoxy, halo-substituted-C1-6alkoxy, —C(O)R23, and —C(O)OR23;
• wherein R23 is selected from hydrogen and C1-6alkyl;
• R4 is selected from R8 and —C(O)OR8;
• wherein R8 is selected from C1-6alkyl, C6-10aryl, C1-10heteroaryl, C3-8cycloalkyl and C3-8heterocycloalkyl;
• wherein said aryl, heteroaryl, cycloalkyl or heterocycloalkyl of R8 is optionally substituted with 1 to 3 radicals independently selected from halo, C1-6alkyl, C3-8cycloalkyl, C3-8heterocycloalkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, C1-6alkoxy and halo-substituted-C1-6alkoxy;
• R5 is selected from hydrogen, C1-6alkyl, halo-substituted-C1-6alkyl, hydroxy-substituted-C1-6alkyl, C1-6alkoxy and halo-substituted-C1-6alkoxy;
• or the pharmaceutically acceptable salts thereof.